Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855771 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT06855771: Recruiting Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.
NCT06855771 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 130 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06855771, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Primary Outcome
OR is defined as confirmed complete response (CR) or partial response (PR)
Conditions Studied
Interventions
- DRUG BMS-986504
Study Locations (20)
New York
- Memorial Sloan Kettering Cancer Center - New York
- Local Institution - 0079 - Shirley
Oregon
- Providence Portland Medical Center - Portland
- Oregon Health and Science University - Portland
New South Wales
- GenesisCare - Campbelltown - Campbelltown
- Chris O'Brien Lifehouse - Camperdown
Alaska
- Alaska Oncology and Hematology - Anchorage
Idaho
- Local Institution - 0099 - Boise
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2031-12-30 |
| Phase | Phase 2 |
What NCT06855771 shows while recruiting
NCT06855771 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which BMS-986504 is the first listed.
NCT06855771 names 20 study sites across 17 states, led by New York, Oregon, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06855771 about?
NCT06855771 is a clinical study titled "A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)". The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
What is the current status of trial NCT06855771?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-09-09. Estimated completion is 2031-12-30.
What conditions does trial NCT06855771 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06855771?
The interventions under investigation include: BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT06855771?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855771 being conducted?
This trial has 20 study locations across Alaska, Idaho, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06855771's enrollment target sits among peer trials
130 62nd of 130 higher than 68 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
RECRUITING · Phase 2
-
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
RECRUITING · Phase 2
-
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
RECRUITING · Phase 2
-
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RECRUITING · Phase 2
-
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI